Chris Degnan, the Chief Financial Officer of UroGen Pharma Ltd., has reported significant stock transactions in a recent SEC filing. On October 8, 2026, Degnan acquired 4,483 ordinary shares and disposed of 2,202 shares. This activity highlights his ongoing commitment to the company and may reflect confidence in its future performance.
Background
UroGen Pharma Ltd. is a company focused on developing innovative therapies for urological diseases. It operates within the pharmaceutical preparations sector, classified under the Standard Industrial Classification (SIC) code 2834. The company is publicly traded under the ticker symbol URGN.
What the Filing Says
The filing, with accession number 0001437749-26-032421, details Degnan's transactions. He acquired 4,483 ordinary shares and disposed of 2,202 shares at a price of $36.69 per share. Following these transactions, Degnan now holds a total of 4,561 shares.
Impact
These transactions may affect UroGen's investor relations and market perception, as they indicate the CFO's active involvement in the company's stock. The pharmaceutical preparations industry often scrutinizes insider trading, and such disclosures can influence investor confidence.
What's Next
The filing does not say what happens next.
Additional Insights from the Filing
The filing also indicates that Chris Degnan's transactions included the acquisition of 4,483 restricted stock units (RSUs) on the same date, October 8, 2026. These RSUs represent a contingent right to receive ordinary shares of UroGen Pharma Ltd. The RSUs were granted as part of his compensation and will vest in three equal annual installments starting from October 8, 2025.
Furthermore, the filing notes that the 2,202 shares disposed of by Degnan were sold to satisfy withholding tax obligations upon the settlement of the restricted stock units. This detail underscores the financial planning involved in managing his equity compensation.
Ownership Summary
Following these transactions, Degnan's total ownership of UroGen Pharma Ltd. shares stands at 4,561 ordinary shares. This reflects a direct ownership, as indicated in the filing.
Company Information
UroGen Pharma Ltd. is incorporated in L3, with its business address located at 9 Ha'Ta'asiya St, Ra'anana, L3, 4365007. The company operates in the pharmaceutical preparations sector, classified under the SIC code 2834, and is publicly traded under the ticker symbol URGN.
"The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025."